This trial will test whether LNP023 is better than placebo at reducing proteinuria and slowing renal disease progression in people with primary IgA nephropathy.
- Immunoglobulin A Nephropathy
2 Primary · 8 Secondary · Reporting Duration: Up to 24 months
Side Effects for
2 Treatment Groups
LNP023 200mg b.i.d
1 of 2
Placebo to LNP023 200mg b.i.d
1 of 2
450 Total Participants · 2 Treatment Groups
Primary Treatment: LNP023 · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|Novartis Investigative Site||100.0%|
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novartis Investigative Site: < 48 hours
Average response time
- < 2 Days
- Reich, Heather N., and Jürgen Floege. 2022. “How I Treat Iga Nephropathy”. Clinical Journal of the American Society of Nephrology. American Society of Nephrology (ASN). doi:10.2215/cjn.02710322.
- Reich HN, Floege J. How I Treat IgA Nephropathy. Clin J Am Soc Nephrol. 2022 Aug;17(8):1243-1246. doi: 10.2215/CJN.02710322. Epub 2022 Jun 8. No abstract available.
- 2021. "Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04578834.
Frequently Asked Questions
What is the ideal sample size for this research?
"That is accurate. The clinical trial was originally advertised on January 25th, 2021 and was last updated on November 7th, 2022. The study is hoping to enroll 450 patients from 42 different sites." - Anonymous Online Contributor
Are there any observed side effects of LNP023?
"LNP023 has been given a safety score of 3 by our team at Power. This is because LNP023 is in Phase 3 trials, meaning that there is both efficacy data and multiple rounds of safety data available." - Anonymous Online Contributor
Are there different hospitals conducting this research in Canada?
"This research is currently being conducted at 42 different locations, which include El Paso, Rochester, and Marshfield. To minimize potential participant burden, it is recommended to choose a location nearest to you." - Anonymous Online Contributor
Are there any other instances where LNP023 has been tested in a clinical setting?
"LNP023 was first studied in 2019 at Novartis Investigative Site. Since then, there have been 18270 completed clinical trials. There are 10 active studies as of now, with a few of these trials taking place in El Paso, Texas." - Anonymous Online Contributor